NYSE:AGNAllergan Stock Price, Forecast & News

Allergan's stock was trading at $185.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AGN shares have increased by 4.1% and is now trading at $193.02. View which stocks have been most impacted by Coronavirus.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 13 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Allergan.

Allergan is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Allergan.

Allergan plc (NYSE:AGN) posted its earnings results on Monday, February, 10th. The company reported $5.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.57 by $0.65. The business earned $4.35 billion during the quarter, compared to analysts' expectations of $4.09 billion. Allergan had a positive return on equity of 8.46% and a negative net margin of 15.44%. The firm's revenue for the quarter was up 6.6% on a year-over-year basis. During the same period in the prior year, the firm earned $4.29 EPS. View Allergan's earnings history.

Allergan declared a quarterly dividend on Wednesday, March 18th. Investors of record on Thursday, April 16th will be given a dividend of $0.74 per share on Monday, June 15th. This represents a $2.96 annualized dividend and a dividend yield of 1.53%. The ex-dividend date is Wednesday, April 15th. View Allergan's dividend history.

Allergan announced that its Board of Directors has approved a stock buyback program on Tuesday, January 29th 2019, which permits the company to repurchase $2,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to reacquire up to 4.1% of its shares through open market purchases. Shares repurchase programs are often a sign that the company's board believes its shares are undervalued.

14 Wall Street analysts have issued twelve-month price objectives for Allergan's stock. Their forecasts range from $154.00 to $203.00. On average, they expect Allergan's share price to reach $183.73 in the next year. This suggests that the stock has a possible downside of 4.8%. View analysts' price targets for Allergan.

Media coverage about AGN stock has trended negative on Tuesday, according to InfoTrie. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Allergan earned a coverage optimism score of -2.6 on InfoTrie's scale. They also gave news articles about the company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutAllergan.

Some companies that are related to Allergan include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Zoetis (ZTS), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.42%), State Street Corp (4.15%), Longview Partners Guernsey LTD (1.52%), Clearbridge Investments LLC (1.24%), JPMorgan Chase & Co. (1.12%) and Morgan Stanley (0.84%). Company insiders that own Allergan stock include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi and Matthew M Walsh. View institutional ownership trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including Longview Partners Guernsey LTD, Nuveen Asset Management LLC, Clearbridge Investments LLC, State Street Corp, Segantii Capital Management Ltd, Scharf Investments LLC, Canyon Capital Advisors LLC, and Mackenzie Financial Corp. View insider buying and selling activity for Allergan.

AGN stock was acquired by a variety of institutional investors in the last quarter, including Syquant Capital Sas, JPMorgan Chase & Co., ING Groep NV, BlackRock Inc., Water Island Capital LLC, Maso Capital Partners Ltd, Glazer Capital LLC, and Swiss National Bank. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, and Matthew M Walsh. View insider buying and selling activity for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $193.02.

Allergan has a market capitalization of $63.50 billion and generates $16.09 billion in revenue each year. The company earns $-5,271,000,000.00 in net income (profit) each year or $17.64 on an earnings per share basis. Allergan employs 17,400 workers across the globe.

The official website for Allergan is www.allergan.com.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]